Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.1% – Should You Buy?

Denali Therapeutics Inc. (NASDAQ:DNLI) rose 6.1% on Monday . The stock traded as high as $21.23 and last traded at $20.89. Approximately 544,351 shares traded hands during trading, a decline of 67% from the average daily volume of 1,636,371 shares. The stock had previously closed at $19.69.

Analysts Set New Price Targets

A number of research firms have weighed in on DNLI. Morgan Stanley reissued an “overweight” rating and set a $40.00 target price on shares of Denali Therapeutics in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus set a $37.00 target price on Denali Therapeutics in a report on Monday, November 17th. Wedbush reduced their price target on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Thursday, December 11th. Finally, Wolfe Research started coverage on Denali Therapeutics in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.20.

Denali Therapeutics Stock Up 7.3%

The firm’s 50-day simple moving average is $19.40 and its 200 day simple moving average is $17.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16. The company has a market cap of $3.35 billion, a P/E ratio of -7.11 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same period last year, the firm earned ($0.67) EPS. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 35,198 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares in the company, valued at approximately $4,897,744.50. This trade represents a 10.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares in the company, valued at approximately $4,666,662. The trade was a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Several large investors have recently made changes to their positions in the stock. Headlands Technologies LLC bought a new position in Denali Therapeutics during the 2nd quarter worth about $26,000. Johnson Financial Group Inc. acquired a new stake in shares of Denali Therapeutics in the 3rd quarter valued at approximately $29,000. State of Wyoming bought a new position in shares of Denali Therapeutics in the 2nd quarter valued at about $29,000. Aster Capital Management DIFC Ltd bought a new position in Denali Therapeutics during the fourth quarter worth about $57,000. Finally, Quarry LP bought a new position in shares of Denali Therapeutics during the 3rd quarter worth approximately $64,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.